Abstract
Evaluating the Efficacy and Safety of Erenumab (AMG 334) In Chronic Migraine Prevention in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study (S52.002)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
